Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
暂无分享,去创建一个
E. Van Cutsem | J. Tabernero | N. Tebbutt | J. Stephenson | E. Mitchell | I. McCaffery | C. Eng | H. Prenen | K. Oliner | J. Gansert | R. Tang | D. Smethurst | E. Nowara | E. Loh | I. Davidenko | A. Świeboda-Sadlej | H. Deng | Lisa Chen | E. Élez
[1] Andrea Bertotti,et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.
[2] R. Donehower,et al. Updated Efficacy, Biomarker, and Exposure-Response Data from a Phase 2 Study of Rilotumumab (R) Plus Epirubicin, Cisplatin, and Capecitabine (ECX) in Gastric (G) or Esophagogastric Junction (EGJ) Cancer , 2012 .
[3] J. Mariadason,et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. , 2012, Clinical colorectal cancer.
[4] P. Lollini,et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling , 2011, Oncogene.
[5] R. Radinsky,et al. Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing's and Osteogenic Sarcoma Models , 2011, Journal of Pharmacology and Experimental Therapeutics.
[6] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[7] L. Trusolino,et al. MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.
[8] J. Christensen,et al. HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation , 2009, Clinical Cancer Research.
[9] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Van Cutsem,et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Solit,et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Berlin,et al. Lack of Correlation between Epidermal Growth Factor Receptor Status and Response to Panitumumab Monotherapy in Metastatic Colorectal Cancer , 2010, Clinical Cancer Research.
[13] C. Mao,et al. Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer , 2010, British Journal of Cancer.
[14] F. Barany,et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. , 2008, Cancer letters.
[15] L. Rosen,et al. A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G) , 2008 .
[16] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Marcin Majka,et al. The biological role of HGF-MET axis in tumor growth and development of metastasis. , 2008, Frontiers in bioscience : a journal and virtual library.
[18] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[19] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Weiser,et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. , 2007, Cancer letters.
[21] H. Lane,et al. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.
[22] N. Anderson,et al. The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[23] W. Birchmeier,et al. Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.
[24] K. L. Pierce,et al. Transactivation of the EGF Receptor Mediates IGF-1-stimulated Shc Phosphorylation and ERK1/2 Activation in COS-7 Cells* , 2000, The Journal of Biological Chemistry.
[25] D. Stolz,et al. Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells* , 2000, The Journal of Biological Chemistry.
[26] J. Swantek,et al. Prolonged activation of ERK2 by epidermal growth factor and other growth factors requires a functional insulin-like growth factor 1 receptor. , 1999, Endocrinology.
[27] R H Hruban,et al. Gene expression profiles in normal and cancer cells. , 1997, Science.
[28] B. Nordlinger,et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.